



CENTER FOR IMPROVING
VALUE IN HEALTH CARE

Data Release Review Committee September 2023 Meeting Agenda

Time	Opportunity Number	Project Title
<u>10:30 AM</u>	24.105.10.3	Division of Insurance Prescription Drug Affordability Board
<u>11:00 AM</u>	24.04	University of Minnesota School of Public Health Presentation and Quality of Care Following the Colorado Option



CENTER FOR IMPROVING
VALUE IN HEALTH CARE

Data Release Review Committee September 2023 Meeting Agenda

10:30 AM – 24.105.10.3, DIVISION OF INSURANCE

State Development

Prescription Drug Affordability Board

Description: Perform analyses to support the Prescription Drug Affordability Board (PDAB) in identifying eligible drugs for an affordability review, prioritizing the list of drugs, assisting in the development of upper payment limits (UPLs), assessing the impact of UPLs on providers, pharmacies, and patient access to care, and validate the use of savings are returned to consumers (particularly in out-of-pocket drug costs).

Business Significance and Triple Aim Impact: To fulfill the requirements of SB 21- 175 which seeks to make prescription drugs more affordable in Colorado through creating more transparency, review of high-cost drugs, and the creation of upper payment limits to decrease costs.

Analytic Steps:

Multiple steps may be necessary to fulfill the different requirements from the legislation.

Identify a list of drugs that qualify for an affordability review by the board

Use a combination of claims and WAC data (the Division will bring into the DataMart from Analysource through our own access) to identify any prescription drug that meets the cost thresholds as outlined in CRS 10-16-1406. This will include reviewing utilization in claims to define a course of treatment and the average cost per year or course of treatment and analyzing average out of pocket costs.

Assist the board in prioritizing the list with additional detail about populations, utilization, and costs of the identified drugs. This may include using information from the Transparency report provided by CIVHC

Answer ad-hoc questions for DOI staff and the board in assessing which drugs on the list should undergo an affordability review as well as answering ad-hoc questions during the review.



CENTER FOR IMPROVING
VALUE IN HEALTH CARE

Data Release Review Committee September 2023 Meeting Agenda

11:00 AM – 24.04, UNIVERSITY OF MINNESOTA SCHOOL OF PUBLIC HEALTH

Limited Extract

Presentation and Quality of Care Following the Colorado Option

This project will examine private claims data between the years 2021 and 2023 to identify the impact of the newly offered Colorado Option standardized plans on patient presentation and emergency health services.

In 2021 Colorado passed HB21-1232 to establish a Marketplace-based public option, called the Colorado Option. Under the legislation, Colorado's Division of Insurance created a standardized plan with a regulated benefit design. Insurers already selling individual and family coverage must offer a Colorado Option in each county they sell other individual and small group plans.¹ While the benefit design of each insurer's Colorado Option plan does not vary, there are differences between premiums, provider networks, and customer service among the choices. Moreover, when considering a single insurer in Colorado's Marketplace, there are differences between their Colorado Option standardized plan and their existing, non-standardized Marketplace offerings.

While the Colorado Option aims to lower premiums, improve racial health equity, and increase both access as well as affordability of coverage², it is not clear how the policy has affected consumers and whether the Colorado Option is associated with different accessibility and utilization of health care services between individuals in the Marketplace that enroll in a Colorado Option plan versus those who enroll in a non-Colorado Option plan. This project will use the state of Colorado's All Payer Claims Database (APCD) data to find preliminary evidence on the Colorado Option's impact on patient presentation and health service utilization in its first year.

The structure of APCD data allows two different levels of comparison: within the Marketplace and between years. By looking at 2023 Marketplace claims, I will consider individuals enrolled in a Colorado Option plan in one category and those enrolled in a non-Colorado Option plan as a comparison. Utilizing variables on source of care, diagnosis, and procedure in the APCD will enable me to identify any differences between the presentation and utilization trends of these groups. Moreover, by looking at claims from 2021 through 2023, I can estimate the impact of the Colorado Option as a policy by identifying differences in health service utilization for those with Marketplace plan pre- and post- the implementation of the Colorado Option.

¹ Colorado Department of Regulator Agencies. "Colorado Option 2023 Standard Plans: Quality and Affordable Health Insurance Coverage." Accessed 7/20/2023. <https://drive.google.com/file/d/1HcCxoBi76XCHEwVN3O3qKbPUa6vdkFAk/view>

² Colorado Department of Regulatory Agencies. "Overview of Colorado Option." Accessed 7/20/2023. https://drive.google.com/file/d/1ELKxg9ZHwBWsFjND96e3Lalul_oX8ZYG/view



CENTER FOR IMPROVING
VALUE IN HEALTH CARE

Data Release Review Committee September 2023 Meeting Agenda